Skip to main content
Erschienen in: Current Rheumatology Reports 2/2011

01.04.2011

Quality of Care in Patients with Gout: Why is Management Suboptimal and What Can Be Done About It?

verfasst von: N. Lawrence Edwards

Erschienen in: Current Rheumatology Reports | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Gout is a common inflammatory arthritis. We know a great deal about its etiopathogenesis and have relatively safe and effective therapies for it. Gout, however, remains a poorly managed disease with mistakes made in securing an accurate diagnosis and in using appropriate therapies for acute and chronic stages of the disease. Synovial fluid analysis with polarizing microscopy is the “gold standard” for confirming the diagnosis of gout but has been used in fewer than 10% of all patients diagnosed with gout. The newly adopted European clinical guidelines offer a practical alternative to synovial fluid analysis, but primary care physicians are not well-versed in their use. Other serious errors in the management of gout are related to the use of medications to treat acute and chronic gout. Frequently, the anti-inflammatory drugs used to treat acute symptoms and urate-lowering drugs used to prevent long-term destruction are improperly dosed, leading to dissatisfaction on the part of patients and physicians. Widespread education about evidence-based diagnostic and treatment guidelines is desperately needed.
Literatur
1.
Zurück zum Zitat Edwards NL. Crystal deposition diseases. In Cecil’s Textbook of Medicine. 24th Edition, 2010. Edwards NL. Crystal deposition diseases. In Cecil’s Textbook of Medicine. 24th Edition, 2010.
2.
Zurück zum Zitat Pascual E, Sivera F, Why is gout so poorly managed? Ann Rheum Disease 2007: 66;1269–1270.CrossRef Pascual E, Sivera F, Why is gout so poorly managed? Ann Rheum Disease 2007: 66;1269–1270.CrossRef
3.
Zurück zum Zitat McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54:452–60.PubMed McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54:452–60.PubMed
4.
Zurück zum Zitat Schlesinger N, Baker DG, Schumacher HR Jr. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol 1999; 11:441–5.PubMedCrossRef Schlesinger N, Baker DG, Schumacher HR Jr. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol 1999; 11:441–5.PubMedCrossRef
5.
Zurück zum Zitat Zhang W, Doherty M, Pascual E et al.: EULAR evidence-based recommendations for gout. Part I. Diagnosis. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Disease 2006; 65:1301–11.CrossRef Zhang W, Doherty M, Pascual E et al.: EULAR evidence-based recommendations for gout. Part I. Diagnosis. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Disease 2006; 65:1301–11.CrossRef
6.
Zurück zum Zitat Mikuls TR, Farrar JT, Bilker WB et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005: 44;1038–1042.PubMedCrossRef Mikuls TR, Farrar JT, Bilker WB et al. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricemia: results from the UK General Practice Research Database (GPRD). Rheumatology 2005: 44;1038–1042.PubMedCrossRef
7.
Zurück zum Zitat Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Disease 2007: 66;1311–1315.CrossRef Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Disease 2007: 66;1311–1315.CrossRef
8.
Zurück zum Zitat Pal B, Foxall M, Dysart T, et al. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000: 19;21–25.PubMedCrossRef Pal B, Foxall M, Dysart T, et al. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000: 19;21–25.PubMedCrossRef
9.
Zurück zum Zitat ••Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6:30–38. Evidence-based strategies for using established and inexpensive drugs are defined, and recommendations for the use of novel targeted approaches are outlined in this review. PubMedCrossRef ••Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6:30–38. Evidence-based strategies for using established and inexpensive drugs are defined, and recommendations for the use of novel targeted approaches are outlined in this review. PubMedCrossRef
10.
Zurück zum Zitat Edwards NL. Management of Hyperuricemia. In, Arthritis and Allied Conditions 16th Edition (ed WJ Koopman) Williams and Wilkins (Baltimore), 2009. Edwards NL. Management of Hyperuricemia. In, Arthritis and Allied Conditions 16th Edition (ed WJ Koopman) Williams and Wilkins (Baltimore), 2009.
11.
Zurück zum Zitat •• Edwards NL. Treatment failure gout: a moving target. Arthritis Rheum 2008: 58;2587–2590. Established ULTs allopurinol and probenecid have historically been misunderstood and misused by physicians, leading to the belief that failures in treating gout were the fault of the medication and not of the prescribing habits. PubMedCrossRef •• Edwards NL. Treatment failure gout: a moving target. Arthritis Rheum 2008: 58;2587–2590. Established ULTs allopurinol and probenecid have historically been misunderstood and misused by physicians, leading to the belief that failures in treating gout were the fault of the medication and not of the prescribing habits. PubMedCrossRef
12.
Zurück zum Zitat Sarawate CDA, Brewer KK, Yang W et al. Gout medication treatment patterns and adherence to standards of care from managed care perspective. Mayo Clin Proc 2006: 81;925–934.PubMedCrossRef Sarawate CDA, Brewer KK, Yang W et al. Gout medication treatment patterns and adherence to standards of care from managed care perspective. Mayo Clin Proc 2006: 81;925–934.PubMedCrossRef
13.
Zurück zum Zitat Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007: 57;1324–1328.PubMedCrossRef Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007: 57;1324–1328.PubMedCrossRef
14.
Zurück zum Zitat Singh JA, Hodges JS, Toscano JP et al. Quality of care for gout in the U needs improvement. Arthritis Rheum 2007: 57;822–829.PubMedCrossRef Singh JA, Hodges JS, Toscano JP et al. Quality of care for gout in the U needs improvement. Arthritis Rheum 2007: 57;822–829.PubMedCrossRef
15.
Zurück zum Zitat Mikuls TR. Quality of care in gout: from measurement to improvement. Clin Exp Rheumatol 2007: 256(suppl 47); S114–S119. Mikuls TR. Quality of care in gout: from measurement to improvement. Clin Exp Rheumatol 2007: 256(suppl 47); S114–S119.
16.
Zurück zum Zitat Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004: 50;937–943.PubMedCrossRef Mikuls TR, MacLean CH, Olivieri J, et al. Quality of care indicators for gout management. Arthritis Rheum 2004: 50;937–943.PubMedCrossRef
17.
Zurück zum Zitat Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006:33; 104–109.PubMed Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006:33; 104–109.PubMed
18.
Zurück zum Zitat Harrold LR, Yood RA, Mikuls TR et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Disease 2006; 65:1368–72.CrossRef Harrold LR, Yood RA, Mikuls TR et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Disease 2006; 65:1368–72.CrossRef
19.
Zurück zum Zitat Sarawate CA, Patel PA, Schumacher HR et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006; 12:61–5.PubMedCrossRef Sarawate CA, Patel PA, Schumacher HR et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006; 12:61–5.PubMedCrossRef
20.
Zurück zum Zitat Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II. Management: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Disease 2006; 65:1312–24.CrossRef Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II. Management: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Disease 2006; 65:1312–24.CrossRef
21.
Zurück zum Zitat Stamp L, Gow P, Sharples K et al. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 2000; 30:567–72.PubMed Stamp L, Gow P, Sharples K et al. The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 2000; 30:567–72.PubMed
22.
Zurück zum Zitat Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Disease 1998; 57:545–549.CrossRef Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Disease 1998; 57:545–549.CrossRef
23.
Zurück zum Zitat Hande K, Noone R, Stone W. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47–56.PubMedCrossRef Hande K, Noone R, Stone W. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76:47–56.PubMedCrossRef
24.
Zurück zum Zitat Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33: 1646–1650.PubMed Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006, 33: 1646–1650.PubMed
25.
Zurück zum Zitat Vazquez-Mellado J, Meono Morales E, Pacheo-Tena C, et al. Relationship between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Disease 2001; 60:981–983.CrossRef Vazquez-Mellado J, Meono Morales E, Pacheo-Tena C, et al. Relationship between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Disease 2001; 60:981–983.CrossRef
26.
Zurück zum Zitat Becker M, Schumacher HJ, Wortmann R et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450–61.PubMedCrossRef Becker M, Schumacher HJ, Wortmann R et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450–61.PubMedCrossRef
27.
Zurück zum Zitat •• Singh J, Strand V. Gout is associated with more comorbidity, poorer health-related quality of life and higher health care utilization in US veterans. Ann Rheum Disease 2008; 67:1310–1316. This population-based, health-related quality-of-life assessment in US veterans with gout showed greater health care use, functional disability, and 1-year unadjusted mortality rates compared with non-gouty veterans. CrossRef •• Singh J, Strand V. Gout is associated with more comorbidity, poorer health-related quality of life and higher health care utilization in US veterans. Ann Rheum Disease 2008; 67:1310–1316. This population-based, health-related quality-of-life assessment in US veterans with gout showed greater health care use, functional disability, and 1-year unadjusted mortality rates compared with non-gouty veterans. CrossRef
28.
Zurück zum Zitat Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28:577–80.PubMed Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28:577–80.PubMed
29.
Zurück zum Zitat Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51:321–5.PubMedCrossRef Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51:321–5.PubMedCrossRef
30.
Zurück zum Zitat Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450–61.PubMedCrossRef Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450–61.PubMedCrossRef
31.
Zurück zum Zitat Perez-Ruiz F, Calabozo M. Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999; 5:49–55.PubMedCrossRef Perez-Ruiz F, Calabozo M. Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999; 5:49–55.PubMedCrossRef
32.
Zurück zum Zitat Perez-Ruiz F, Calabrozo M, Herrero-Beites AM, Garcia-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000; 86:287–91.PubMedCrossRef Perez-Ruiz F, Calabrozo M, Herrero-Beites AM, Garcia-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000; 86:287–91.PubMedCrossRef
33.
Zurück zum Zitat Siu Y-P, Leung KT, Tong MKH, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kid Disease. 2006; 47:51–59.CrossRef Siu Y-P, Leung KT, Tong MKH, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kid Disease. 2006; 47:51–59.CrossRef
Metadaten
Titel
Quality of Care in Patients with Gout: Why is Management Suboptimal and What Can Be Done About It?
verfasst von
N. Lawrence Edwards
Publikationsdatum
01.04.2011
Verlag
Current Science Inc.
Erschienen in
Current Rheumatology Reports / Ausgabe 2/2011
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0154-6

Weitere Artikel der Ausgabe 2/2011

Current Rheumatology Reports 2/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.